A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the ...

A recent article posted to the Research Square* preprint server illustrated that early intervention with azelastine nasal spray therapy might lower the severe acute respiratory syndrome coronavirus 2 ...

Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research & Development Corp. has announced the launch of FabiSpray, a nitric oxide nasal spray (NONS), for the treatment ...

Glenmark pharma’s nasal spray administered to adult Covid-19 patients showed reduction of the viral load by 94% within 24 hours and by 99% in 48 hours, according to the phase 3 trial results published ...

VANCOUVER, British Columbia & MUMBAI, India--(BUSINESS WIRE)--SaNOtize Research & Development Corp., (“SaNOtize”), a Canadian anti-infective-focused therapeutics ...

The second wave of the coronavirus disease (Covid-19) continues to wreak havoc across the world. Several countries have expanded their vaccination drives and are administering doses to children and ...

Corona Cases In India: The number of covid cases has started increasing again; in the last 24 hours, more than 20,000 new cases have been registered, the highest after 145 days. Covid vaccination and ...

Covid Nasal Spray: A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of ...

The trial evaluated a seven-day treatment of NONS plus standard of care versus placebo nasal spray and standard care in patients with symptomatic COVID-19. (Representational image: Reuters) A nasal ...

A nasal spray administered in high-risk adult Covid-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the ...